Company Profile
Harmony Biosciences Stock Price, News & Analysis
- Ticker:
- HRMY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
38.75 USD (+1.33%)
Close
Last updated: August 6, 2026
1.79B USD
Market cap
Why the stock is moving
The latest company update was “Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium”. HRMY changed 1.33% and closed at $38.75 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Sleep and Neurologic Disorders
Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.
WAKIX Franchise
WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.
Pitolisant Lifecycle Programs
Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.
Orexin-2 Program
BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.
Future catalysts
NDA submission for a gastro-resistant formulation of pitolisant in the second quarter of 2026.
Phase 1 pharmacokinetic data for BP-205 around mid-2026.
Phase 3 data for high-dose pitolisant in 2027.
Recent news
- 01
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
Source: Harmony Biosciences
- 02
- 03
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Source: Harmony Biosciences
- 04
- 05
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Source: Harmony Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Harmony Biosciences (HRMY)?
Harmony Biosciences (HRMY) most recently closed at 38.75 USD, a +1.33% move versus the previous session.
What is the market cap of Harmony Biosciences (HRMY)?
Harmony Biosciences currently has a market capitalization of 1.79B USD on BioPharmSignal.
What does Harmony Biosciences do?
Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal...
On which exchange is HRMY stock listed?
Harmony Biosciences (HRMY) is associated with NASDAQ, United States, Biopharma.
What is BP-205?
Phase 1 pharmacokinetic data for BP-205 around mid-2026.
Which conditions is Harmony Biosciences targeting with BP-205?
Phase 1 pharmacokinetic data for BP-205 around mid-2026.
How does Harmony Biosciences describe recent progress with BP-205?
Phase 1 pharmacokinetic data for BP-205 around mid-2026.
What is Sleep?
Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases.